HRP20100283T1 - Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor - Google Patents

Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor Download PDF

Info

Publication number
HRP20100283T1
HRP20100283T1 HR20100283T HRP20100283T HRP20100283T1 HR P20100283 T1 HRP20100283 T1 HR P20100283T1 HR 20100283 T HR20100283 T HR 20100283T HR P20100283 T HRP20100283 T HR P20100283T HR P20100283 T1 HRP20100283 T1 HR P20100283T1
Authority
HR
Croatia
Prior art keywords
methyl
pyrazol
dichlorophenyl
bromophenyl
ethyl
Prior art date
Application number
HR20100283T
Other languages
English (en)
Inventor
Barth Francis
Congy Chistian
Martinez Serge
Rinaldi-Carmona Murielle
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20100283T1 publication Critical patent/HRP20100283T1/hr
Publication of HRP20100283T8 publication Critical patent/HRP20100283T8/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)

Abstract

Spoj koji odgovara formuli (I): naznačen time što: R1 predstavlja (C1-C6)alkil; (C3-C7)cikloalkil koji je nesupstituiran ili supstituiran jednom ili nekoliko puta s (C1-C3)alkil skupinom; (C3-C7)cikloalkilmetil koji je nesupstituiran ili supstituiran jednom ili nekoliko puta na karbociklu s (C1-C3)alkilom; fenil koji je nesupstituiran ili mono-, di- ili trisupstituiran sa supstituentom nezavisno odabranim od atoma halogena, (C1-C4)alkila, (C1-C3)alkoksi, cijano, trifluormetil radikala, trifluormetoksi radikala, S(O)nAlk skupine, (C1-C3)alkilkarbonil skupine, fenila; benzil koji je nesupstituiran ili mono- ili disupstituiran sa supstituentom nezavisno odabranim od atoma halogena, (C1-C3)alkila, (C1-C3)alkoksi; trifluormetil radikala; tienil koji je nesupstituiran ili supstituiran s atomom halogena ili s izoksazolilom; R2 predstavlja atom vodika ili (C1-C3)alkil; R3 predstavlja atom vodika ili (C1-C5)alkil; R4, R5, R6, R7, R8 i R9 svaki nezavisno predstavljaju atom vodika, atom halogena, (C1-C7)alkil, (C1-C5)alkoksi, trifluormetil radikal ili S(O)nAlk skupinu; n predstavlja 0, 1 ili 2; Alk predstavlja (C1-C4)alkil, u obliku baze ili adicijske soli s kiselinom, i u obliku hidrata ili solvata. Patent sadrži još 6 patentnih zahtjeva.

Claims (7)

1. Spoj koji odgovara formuli (I): [image] naznačen time što: R1 predstavlja (C1-C6)alkil; (C3-C7)cikloalkil koji je nesupstituiran ili supstituiran jednom ili nekoliko puta s (C1-C3)alkil skupinom; (C3-C7)cikloalkilmetil koji je nesupstituiran ili supstituiran jednom ili nekoliko puta na karbociklu s (C1-C3)alkilom; fenil koji je nesupstituiran ili mono-, di- ili trisupstituiran sa supstituentom nezavisno odabranim od atoma halogena, (C1-C4)alkila, (C1-C3)alkoksi, cijano, trifluormetil radikala, trifluormetoksi radikala, S(O)nAlk skupine, (C1-C3)alkilkarbonil skupine, fenila; benzil koji je nesupstituiran ili mono- ili disupstituiran sa supstituentom nezavisno odabranim od atoma halogena, (C1-C3)alkila, (C1-C3)alkoksi; trifluormetil radikala; tienil koji je nesupstituiran ili supstituiran s atomom halogena ili s izoksazolilom; R2 predstavlja atom vodika ili (C1-C3)alkil; R3 predstavlja atom vodika ili (C1-C5)alkil; R4, R5, R6, R7, R8 i R9 svaki nezavisno predstavljaju atom vodika, atom halogena, (C1-C7)alkil, (C1-C5)alkoksi, trifluormetil radikal ili S(O)nAlk skupinu; n predstavlja 0, 1 ili 2; Alk predstavlja (C1-C4)alkil, u obliku baze ili adicijske soli s kiselinom, i u obliku hidrata ili solvata.
2. Spoj formule (I) prema zahtjevu 1, naznačen time što: R1 predstavlja etil, izopropil, n-butil; cikloheksil; cikloheksilmetil; 2-klorfenil, 3-klorfenil, 2-fluorfenil, 3-klor-4-fluorfenil, 4-bromo-2-etilfenil, 3-metilfenil, 4-terc-butilfenil, 3,5-dimetilfenil, 3-metoksifenil, 4-metoksifenil, 3-cijanofenil, 4-cijanofenil, 2-(trifluormetil)fenil, 3-(trifluormetil)fenil, 4-(trifluormetil)fenil, 3,5-bis(trifluormetil)fenil, 2-(trifluormetoksi)fenil, 3-(trifluormetoksi)fenil, 2-(metilsulfonil)-fenil, 3-(metilsulfonil)fenil, 3-acetilfenil, 3-bifenil, 2-bifenil; 3-klorbenzil, 2-fluorbenzil, 4-fluorbenzil, 3-(trifluormetil)benzil, 4-(trifluormetil)benzil; 5-brom-2-tienil; 5-izoksazol-3-il-2-tienil; R2 predstavlja atom vodika ili metil; R3 predstavlja metil ili etil; R4 predstavlja atom vodika; R5 je na položaju 4 fenila i predstavlja atom broma, klora ili fluora, ili metoksi; R6 predstavlja atom vodika; R7 predstavlja atom vodika; R8 je na položaju 4 fenila i predstavlja atom vodika, atom klora, atom fluora; R9 je na položaju 2 fenila i predstavlja atom klora ili fluora; u obliku baze ili adicijske soli s kiselinom, i u obliku hidrata ili solvata.
3. Spoj formule (I) prema zahtjevu 1, naznačen time što je odabran iz sljedeće skupine: N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]butan-1-sulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-cikloheksansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-cikloheksilmetansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-klorbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-4-terc-butilbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-4-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-4-(trifluormetil)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-2-(metilsulfonil)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-1-(3-klorfenil)metansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-1-[3-(trifluormetil)fenil]metansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-klor-4-fluorbenzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-butan-1-sulfonamid; 3-klor-N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]benzensulfonamid; 4-terc-butil-N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]benzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-metoksibenzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-cijanobenzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-4-(trifluormetil)benzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-2-(trifluormetoksi)benzensulfonamid; N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-2-(metilsulfonil)benzensulfonamid; 3-klor-N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-4-fluorbenzensulfonamid; 4-bromo-N-[[5-(4-klorfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-2-etilbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]etansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]propan-2-sulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]butan-1-sulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-cikloheksansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-1-cikloheksilmetansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3-klorbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-2-klorbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3-metilbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-4-terc-butilbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-4-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-4-(trifluormetil)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3-(trifluormetil)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-2-(trifluormetil)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3-(trifluormetoksi)benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-2-(trifluormetoksi)benzensulfonamid; 3-acetil-N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]benzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]bifenil-3-sulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-1-[4-(trifluormetil)fenil]metansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-1-[3-(trifluormetil)fenil]metansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3,5-dimetilbenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-3,5-bis(trifluormetil)benzensulfonamid; 3-klor-N-[[1-(2-klorfenil)-5-(4-klorfenil)-4-metil-1H-pirazol-3-il]metil]benzensulfonamid; N-[[1-(2-klorfenil)-5-(4-klorfenil)-4-metil-1H-pirazol-3-il]metil]-2-fluorbenzensulfonamid; N-[[1-(2-klorfenil)-5-(4-klorfenil)-4-metil-1H-pirazol-3-il]metil]-3-cijanobenzensulfonamid; N-[[1-(2-klorfenil)-5-(4-klorfenil)-4-metil-1H-pirazol-3-il]metil]-3-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-metoksibenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-metil-1H-pirazol-3-il]metil]-3-cijanobenzensulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-1-(2-fluorfenil)metansulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-1-(4-fluorfenil)metansulfonamid; 5-bromo-N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]tiofen-2-sulfonamid; N-[[5-(4-bromfenil)-1-(2,4-diklorfenil)-4-etil-1H-pirazol-3-il]metil]-5-izoksazol-3-iltiofen-2-sulfonamid; 3-klor-N-[[1-(2,4-diklorfenil)-5-(4-metoksifenil)-4-metil-1H-pirazol-3-il]metil]benzensulfonamid; N-[[1-(2,4-diklorfenil)-5-(4-metoksifenil)-4-metil-1H-pirazol-3-il]metil]-3-metilbenzensulfonamid; u obliku baze ili adicijske soli s kiselinom, i u obliku hidrata ili solvata.
4. Postupak za dobivanje spojeva formule (I) prema zahtjevu 1, naznačen time što: spoj formule: [image] u kojoj R2, R3, R4, R5, R6, R7, R8 i R9 su kao što je definirano za spoj formule (I) u zahtjevu 1, reagira, u prisutnosti baze i u otapalu, sa sulfonil halogenidom formule: [image] u kojoj R1 je kao što je definirano za spoj formule (I) u zahtjevu 1 i Hal predstavlja atom halogena.
5. Lijek, naznačen time što sadržava spoj formule (I) prema bilo kojem od zahtjeva 1 do 3, ili adicijske soli ovog spoja s farmaceutski prihvatljivom kiselinom, ili hidrat ili solvat spoja formule (I).
6. Farmaceutski pripravak, naznačen time što sadržava spoj formule (I) prema bilo kojem od zahtjeva 1 do 3, ili farmaceutski prihvatljivu sol, hidrat ili solvat ovog spoja, i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo.
7. Upotreba spoja formule (I) prema bilo kojem od zahtjeva 1 do 3, naznačena time što se upotrebljava za dobivanje lijeka namijenjenog liječenju i prevenciji poremećaja apetita, gastrointestinalnih poremećaja, upalnih fenomena, bolesti imunološkog sustava, psihotičnih poremećaja, ovisnosti o alkoholu i ovisnosti o nikotinu.
HR20100283T 2004-01-12 2010-05-21 Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor HRP20100283T8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400257A FR2864958B1 (fr) 2004-01-12 2004-01-12 Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
PCT/FR2005/000031 WO2005073197A1 (fr) 2004-01-12 2005-01-07 Derives de n-` (1,5-diphenyl-1h-pyrazol-3-yl) sulfonamide avec une affinite pour les recepteurs cb1

Publications (2)

Publication Number Publication Date
HRP20100283T1 true HRP20100283T1 (hr) 2010-08-31
HRP20100283T8 HRP20100283T8 (hr) 2010-10-31

Family

ID=34684951

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100283T HRP20100283T8 (hr) 2004-01-12 2010-05-21 Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor

Country Status (31)

Country Link
US (1) US7294645B2 (hr)
EP (1) EP1720837B1 (hr)
JP (1) JP4723514B2 (hr)
KR (1) KR20060105050A (hr)
CN (1) CN1910157A (hr)
AR (1) AR047096A1 (hr)
AT (1) ATE465995T1 (hr)
AU (1) AU2005209441B2 (hr)
CA (1) CA2551141C (hr)
CR (1) CR8468A (hr)
CY (1) CY1110651T1 (hr)
DE (1) DE602005020907D1 (hr)
DK (1) DK1720837T3 (hr)
EC (1) ECSP066695A (hr)
ES (1) ES2344850T3 (hr)
FR (1) FR2864958B1 (hr)
HR (1) HRP20100283T8 (hr)
IL (1) IL176710A0 (hr)
MA (1) MA28422B1 (hr)
NO (1) NO20063621L (hr)
NZ (1) NZ548442A (hr)
PL (1) PL1720837T3 (hr)
PT (1) PT1720837E (hr)
RS (1) RS51365B (hr)
RU (1) RU2366657C2 (hr)
SI (1) SI1720837T1 (hr)
TN (1) TNSN06203A1 (hr)
TW (1) TWI323255B (hr)
UA (1) UA85079C2 (hr)
WO (1) WO2005073197A1 (hr)
ZA (1) ZA200605657B (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
FR2880023B1 (fr) 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
FR2880890B1 (fr) * 2005-01-19 2007-03-30 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
FR2894579B1 (fr) * 2005-12-12 2008-01-18 Sanofi Aventis Sa Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
FR2894578B1 (fr) * 2005-12-12 2008-02-01 Sanofi Aventis Sa Derives heterocycliques, leur preparation et leur application en therapeutique.
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
ATE469129T1 (de) * 2006-07-11 2010-06-15 Sanofi Aventis N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide
JP2008019205A (ja) * 2006-07-12 2008-01-31 Sanofi-Aventis Ｎ−［（１，５−ジフェニル−１ｈ−ピラゾール−３−イル）メチル］スルホンアミド誘導体、その調製法および治療におけるその応用
US7297710B1 (en) * 2006-07-12 2007-11-20 Sanofi-Aventis Derivatives of N-[(1,5-diphenyl-1H-pyrazol-3-yl)methyl]sulfonamide, their preparation and their application in therapeutics
WO2008062424A2 (en) * 2006-07-31 2008-05-29 Cadila Healthcare Limited Substituted 4,5-dihydro-1h-pyrazole derivatives as cannabinoid modulators
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
EP1911747A1 (en) * 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
FR2911136B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
FR2919184A1 (fr) * 2007-07-26 2009-01-30 Sanofi Aventis Sa L'acide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methylpyrazole-3-carboxylique, ses esters, ses sels pharmaceutiquement acceptables et leurs solvates pour leur utilisation comme medicament.
MX2015002036A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
MX2015002039A (es) * 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirrolopirazoles como bloqueadores del canal de calcio tipo n.
BR112015016323A2 (pt) * 2013-01-17 2017-07-11 Hoffmann La Roche agonistas de receptor de oxitocina para tratamento de doenças de cns
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
KR101685993B1 (ko) * 2014-05-15 2016-12-13 한국과학기술연구원 전압개폐 칼슘이온채널 억제 활성화능을 갖는 ｎ-(피라졸릴메틸)아릴설폰아마이드 화합물 및 이를 포함하는 약학적 조성물
WO2022109292A1 (en) * 2020-11-20 2022-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for inhibiting cb1 activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.

Also Published As

Publication number Publication date
CY1110651T1 (el) 2015-06-10
HRP20100283T8 (hr) 2010-10-31
UA85079C2 (en) 2008-12-25
EP1720837A1 (fr) 2006-11-15
WO2005073197A1 (fr) 2005-08-11
DK1720837T3 (da) 2010-08-23
CA2551141C (fr) 2011-06-07
JP4723514B2 (ja) 2011-07-13
AU2005209441B2 (en) 2010-12-23
DE602005020907D1 (de) 2010-06-10
RS51365B (en) 2011-02-28
SI1720837T1 (sl) 2010-08-31
IL176710A0 (en) 2006-10-31
US7294645B2 (en) 2007-11-13
RU2366657C2 (ru) 2009-09-10
US20070021486A1 (en) 2007-01-25
JP2007517839A (ja) 2007-07-05
AU2005209441A1 (en) 2005-08-11
MA28422B1 (fr) 2007-02-01
PT1720837E (pt) 2010-05-14
EP1720837B1 (fr) 2010-04-28
ATE465995T1 (de) 2010-05-15
KR20060105050A (ko) 2006-10-09
RU2006129297A (ru) 2008-02-20
FR2864958A1 (fr) 2005-07-15
FR2864958B1 (fr) 2006-02-24
PL1720837T3 (pl) 2010-09-30
TNSN06203A1 (en) 2007-11-15
AR047096A1 (es) 2006-01-04
ECSP066695A (es) 2006-10-31
TWI323255B (en) 2010-04-11
ZA200605657B (en) 2007-12-27
CR8468A (es) 2007-03-06
NO20063621L (no) 2006-10-10
TW200535135A (en) 2005-11-01
CA2551141A1 (fr) 2005-08-11
CN1910157A (zh) 2007-02-07
ES2344850T3 (es) 2010-09-08
NZ548442A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
HRP20100283T1 (hr) Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2436780C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2007134383A (ru) Производные 1,5-диарилпиррола, их получение и применение в терапии
RU2007127864A (ru) Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов
RU2374239C2 (ru) Производные арилпиридина
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
AR044163A1 (es) Derivados de pirazol sustituidos, composiciones farmaceuticas que los contienen y compuestos relacionados como antagonistas del receptor de bradiquinina b1
NO20081970L (no) Sulfonamidderivat med PGD2-reseptorantagonistaktivitet
RU2439068C2 (ru) Модуляторы mglur5
JP2006500348A5 (hr)
JP2008545686A5 (hr)
JP2012510989A5 (hr)
JP2008525502A (ja) 抗炎症薬
CA2400141A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
JP2007519754A5 (hr)
CA2553705A1 (en) 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
RU2007133602A (ru) Производные n-[(4,5-дифенил-2-тиенил)метил]амина, их получение и применение в терапии
JP2006524248A5 (hr)
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
JP2008524119A5 (hr)
BRPI0313165B1 (pt) 2-(3-aminoaril)amino-4-aril-tiazóis e sua utilização como inibidores de c-kit
CA2680246A1 (en) Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same
JP2013517273A5 (hr)